

Fecha del CVA

08/04/2026

Parte A. DATOS PERSONALES

Nombre *	Antonia		
Apellidos *	Pineda Bermudez		
Sexo *	Mujer	Fecha de Nacimiento *	23/01/1984
DNI/NIE/Pasaporte *	53368071k	Teléfono *	625841164
URL Web			
Dirección Email	antoniapinedabermudez@gmail.com		
Identificador científico	Open Researcher and Contributor ID (ORCID) *	0000-0002-2315-0293	
	Researcher ID		
	Scopus Author ID		

* Obligatorio

A.1. Situación profesional actual

Puesto	Técnico de laboratorio		
Fecha inicio	2026		
Organismo / Institución	FUNDACION GENERAL DE LA UNIVERSIDAD DE MALAGA		
Departamento / Centro			
País		Teléfono	
Palabras clave			

A.2. Situación profesional anterior

Periodo	Puesto / Institución / País
2018 - 2019	Técnico apoyo a la investigación / INSTITUTO DE BIOMEDICINA DE SEVILLA / España
2007 - 2017	Técnico Laboratorio / NEURON BIOPHARMA, S.A.

A.3. Formación académica

Grado/Master/Tesis	Universidad / País	Año
Ayud. Técnico laboratorio	Aynadar	2006

Parte B. RESUMEN LIBRE DEL CURRÍCULUM

Technician in Pathological Anatomy and Cytodiagnostics, graduated in 2007 from the IES Aynadamar of Granada.

For 10 years (2007-2017) I worked in the company NEURON BIO (Granada), whose main mission was to discover and develop new whose main mission was the discovery and development of new drugs for neurodegenerative diseases.

In this stage I would highlight the participation in the start-up of the laboratory, molecular biology techniques, histology, immunohistochemistry, cell cultures, maintenance of established cell lines, ELISA, determination of biochemical parameters by spectrophotometric biochemical parameters by spectrophotometric techniques, biosafety, cytotoxicity and protection of compounds or extracts on cell cultures.

of compounds or extracts on cell cultures and experimentation with animal models such as mouse and zebrafish. During this period I also acquired extensive experience in R&D management system under standardised work according to UNE 166002.

In 2018, I became part of the staff of FISEVI, within the Oncology Group of the

Virgen del Rocío University Hospital. Here I started working in the field of translational research in oncology, completing my training in different molecular biology techniques, handling of biological samples of human origin and working with clinical databases.

In 2019, I joined the working group of Dr. David Olmos Hidalgo and Dr. Elena Castro, in the context of the IBIMA Genitourinary Tumour Unit (Malaga).

(Malaga). Within this group I am acquiring a wide experience in the field of translational research in prostate cancer, participating in different research projects.

I am participating in different projects of the group in which I am responsible for: classification and cataloguing of samples, processing of tissues from patients, histological staining (immunohistochemistry and immunofluorescence), development of PCR, RT-PCR, IHC, FISH, IF, IHQ techniques, extraction of nucleic acids from paraffin-embedded tissues, preparation of libraries for massive sequencing and creation of databases. Laboratory organisation and management. Operation of semi-automatic scanning platforms such as ARIOL SL-50. Coordination of sample collections and/or biobanks. Supervision of technical and pre-doctoral staff in their training and tasks. Management of orders and purchases of material necessary for the unit. Support to the group leaders in the evaluation tasks of the group's technical staff.

Since 2023 I have been working in Urothelial Cancer, carrying out all the markers for taxonomic classification in bladder cancer, extraction of nucleic acids from paraffin-embedded and frozen tissue, collection of fresh samples in the operating theatre, and management and organisation of the unit.

Parte C. MÉRITOS MÁS RELEVANTES

C.1. Publicaciones

AC: Autor de correspondencia; (nº x / nº y): posición firma solicitante / total autores. Si aplica, indique el número de citaciones

- 1 **Artículo científico.** C Ramirez; S Sierra; I Tercero; JA Vazquez; A Pineda; T Manrique; JS Burgos. 2011. ApoB100/LDLR-/- hypercholesterolaemic mice as a model for mild cognitive impairment and neuronal damage. *Journal alzheimer disease*. 6-7, pp.22712-22713.
- 2 **Artículo científico.** 2025. BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes — doi: 10.1016/j.annonc.2025.05.534.
- 3 **Artículo científico.** C Ramirez; I Tercero; A Pineda; JS Burgos. 2011. Simvastatin is the statin that most efficiently protects against kainate-induced excitotoxicity and memory impairment. *Journal alzheimer disease*. 24-1, pp.164-171.

C.3. Proyectos y Contratos

- 1 **Proyecto.** Optimización de la inmunoterapia en el cáncer de vejiga avanzado mediante la inhibición de la inmunosupresión dependiente de Autotaxina. (Boosting immunotherapy in advanced bladder cancer by targeting Autotaxin-dependent immunosuppression). 01/01/2026-31/08/2028. 170.000 €.
- 2 **Proyecto.** Optimización de la inmunoterapia en el cáncer de vejiga avanzado mediante la inhibición de la inmunosupresión dependiente de Autotaxina (IMMUNEAMBITION). 01/09/2025-31/08/2028. 170.000 €.
- 3 **Proyecto.** Abordando el papel de ATX como nueva diana terapéutica en el cáncer urotelial de vejiga. (FIMABIS). 2022-2025.
- 4 **Proyecto.** DESARROLLO DE BEBIDAS BIOACTIVAS PARA LA MEJORA DE LA SALUD REPRODUCTIVA EN POBLACIÓN ADULTA. (NEURON BIOPHARMA, S.A.). 01/01/2015-31/12/2017. 163.679 €.
- 5 **Proyecto.** OPTIMIZACIÓN Y DESARROLLO PRECLÍNICO DE UN NUEVO FÁRMACO. (Corporación tecnológica andaluza). 01/01/2015-31/12/2015.
- 6 **Proyecto.** UTILIZACIÓN DE ESTATINAS NEUROPROTECTORAS Y ESTRATEGIAS CLÍNICAS PARA ENFERMEDADES DEL SISTEMA NERVIOSOS CENTRAL. (NEURON BIOPHARMA, S.A.). 01/01/2013-31/12/2014.

- 7 **Proyecto.** ENSAYOS DE VALIDACIÓN Y DESARROLLO PRECLÍNICO REGULATORIO DE NUEVAS ESTATINAS NEUROPROTECTORAS. (NEURON BIOPHARMA, S.A.). 01/01/2010-31/12/2012. 5.100 €.
- 8 **Proyecto.** PREVALENCIA, PREDICTORES E IMPLICACIONES CLÍNICAS EN CÁNCER DE PRÓSTATA DE LKAS MUTACIONES GERMINALES EN GENES DE LA REPARACIÓN DEL DNA.. (FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD (FIMABIS)). Desde 2019.
- 9 **Proyecto.** A multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first line of therapy in mCRPC. (Centro Nacional de Investigaciones Oncológicas).
- 10 **Contrato.** Study of prognostic factors in castration-resistant prostate cancer treated with RADIUM-223 David Olmos Hidalgo. 02/01/2016-02/01/2020. 190.000 €.